STMN3 (stathmin 3) is a microtubule-destabilizing protein involved in cytoskeletal regulation and nervous system development. It exhibits intrinsic microtubule depolymerization activity and binds tubulin to regulate microtubule polymerization dynamics 1. STMN3 functions in axonal maintenance through membrane association driven by palmitoylation and undergoes regulated degradation via dual leucine zipper kinase (DLK) signaling 1. In cancer biology, STMN3 has emerged as a disease-relevant gene across multiple malignancies. It is differentially expressed in gastric neuroendocrine carcinomas compared to adenocarcinomas 2 and serves as a component of a nine-gene prognostic signature for bladder cancer patient stratification and immunotherapy response prediction 3. In non-small cell lung cancer, nicotine promotes STMN3 expression in an ID1-dependent manner to facilitate cell proliferation, invasion, and migration 4. STMN3 expression is also regulated by RUNX1 in renal cell carcinoma, where it contributes to extracellular matrix remodeling programs 5. Genetically determined variation at the STMN3/RTEL1 locus associates with glioma risk 6, and STMN3 expression in brain tissues shows causal association with glioma susceptibility 7. STMN3 was also identified as a differentially expressed gene in prostate cancer 8. These findings establish STMN3 as a clinically significant biomarker and potential therapeutic target in cancer progression and neuronal pathologies.